Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs01:15

Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs

413
Bioequivalence experimental study designs play a pivotal role in testing the effectiveness of various treatments. Key among these are the repeated measures, cross-over, carry-over, and Latin square designs. In the repeated measures design, each subject receives all treatments, allowing for temporal comparisons. This type of design is useful in reducing variability but requires careful planning to avoid bias.The cross-over design, an economical method, involves sequential administration of...
413
Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs01:20

Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs

407
Bioequivalence experimental study designs are crucial methodologies used in evaluating and comparing the bioavailability of different drug products. These designs are categorized into various types: completely randomized, randomized block, repeated measures, cross and carry-over, and Latin square designs.Completely randomized designs involve randomly allocating treatments to all subjects participating in the experiment. This allocation is achieved by assigning unique random numbers to subjects...
407
Bioequivalence Data: Statistical Interpretation01:16

Bioequivalence Data: Statistical Interpretation

353
The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...
353
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

230
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
230
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

427
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
427
Bioequivalence: Overview01:16

Bioequivalence: Overview

2.2K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
2.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Paired and AB/BA Cross-Over Design in Early Phase Clinical Trials: A Closer Look at Within-Subject Variance Bias.

Pharmaceutical statistics·2026
Same author

Conformational dynamics of CRISPR-Cas type I-F-HNH inform nickase engineering in a cascade scaffold.

Nucleic acids research·2026
Same author

The novel biomarker t<sup>6</sup>A accurately identified septic patients at admission but failed to predict outcome.

Critical care (London, England)·2025
Same author

Evaluation of Incurred Subject Period Re-analysis (ISPR) as a Tool to Distinguish Fraudulent Pharmacokinetic Profile Pairs from Non-fraudulent Pairs.

The AAPS journal·2024
Same author

Rejoinder to the 'Letter to the Editor' on "Group-by-Treatment Interaction Effects in Comparative Bioavailability Studies".

The AAPS journal·2024
Same author

Conformational landscape of the type V-K CRISPR-associated transposon integration assembly.

Molecular cell·2024

Related Experiment Video

Updated: Apr 24, 2026

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

3.4K

Reference datasets for 2-treatment, 2-sequence, 2-period bioequivalence studies.

Helmut Schütz1, Detlew Labes, Anders Fuglsang

  • 1Consultancy Services for Bioequivalence and Bioavailability Studies, Neubaugasse 36/11, 1070, Vienna, Austria, helmut.schuetz@bebac.at.

The AAPS Journal
|September 13, 2014
PubMed
Summary

Validating statistical software for bioequivalence studies is challenging due to limited public datasets. This study introduces reference datasets and reports results to aid software validation for bioequivalence testing.

More Related Videos

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

30.6K
High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
07:51

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

Published on: May 21, 2018

11.5K

Related Experiment Videos

Last Updated: Apr 24, 2026

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

3.4K
Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

30.6K
High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
07:51

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

Published on: May 21, 2018

11.5K

Area of Science:

  • Pharmacokinetics and Pharmaceutical Sciences
  • Biostatistics
  • Regulatory Science

Background:

  • Validating statistical software for bioequivalence assessment is crucial but hindered by a scarcity of public datasets.
  • Existing public datasets are often of moderate size and balanced, limiting comprehensive software validation.

Purpose of the Study:

  • To introduce reference datasets with varying complexity for bioequivalence studies.
  • To provide point estimates and 90% confidence intervals for these datasets to facilitate software validation.
  • To address the need for robust validation of statistical software in bioequivalence testing.

Main Methods:

  • Generation of reference datasets with diverse characteristics (size, balance, range, outliers, residual error distribution).
  • Analysis of these datasets using commercial (EquivTest, Kinetica, SAS, WinNonlin) and non-commercial (R) software packages.
  • Calculation of point estimates and 90% confidence intervals for bioequivalence parameters.

Main Results:

  • The study presents results from multiple statistical software packages applied to novel reference datasets.
  • Most software packages yielded consistent results, but sequence imbalance highlighted potential issues with one package.
  • The findings underscore the importance of thorough software validation in bioequivalence studies.

Conclusions:

  • The introduced reference datasets serve as a valuable tool for validating statistical software used in bioequivalence studies.
  • Software validation is essential, particularly when dealing with complex or imbalanced study designs.
  • Ensuring accurate statistical software performance is critical for reliable bioequivalence assessment.